Sucampo Pharmaceuticals, Inc. (SCMP) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC lowered its stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 5.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,360 shares of the biopharmaceutical company’s stock after selling 1,378 shares during the quarter. ProShare Advisors LLC owned about 0.06% of Sucampo Pharmaceuticals worth $277,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Louisiana State Employees Retirement System lifted its holdings in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 100 shares during the period. Arizona State Retirement System lifted its holdings in Sucampo Pharmaceuticals by 1.6% in the second quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 200 shares during the period. Capstone Asset Management Co. lifted its holdings in Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 260 shares during the period. Texas Permanent School Fund lifted its holdings in Sucampo Pharmaceuticals by 2.2% in the second quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 398 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Sucampo Pharmaceuticals by 0.9% in the second quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 423 shares during the period. 55.46% of the stock is owned by institutional investors and hedge funds.

Several research firms recently weighed in on SCMP. BidaskClub downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $14.00 to $12.00 in a report on Tuesday, October 3rd. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 4th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Finally, Maxim Group reissued a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Sucampo Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $17.86.

In other news, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Jason Patrick Meyenburg acquired 4,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were acquired at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the acquisition, the insider now directly owns 30,228 shares in the company, valued at $366,665.64. The disclosure for this purchase can be found here. Insiders own 4.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/10/12/sucampo-pharmaceuticals-inc-scmp-shares-sold-by-proshare-advisors-llc.html.

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at 10.25 on Thursday. Sucampo Pharmaceuticals, Inc. has a 1-year low of $9.30 and a 1-year high of $17.55. The firm’s 50-day moving average is $11.65 and its 200-day moving average is $10.72. The stock’s market capitalization is $474.83 million.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm had revenue of $59.90 million for the quarter, compared to analysts’ expectations of $56.44 million. During the same quarter last year, the business earned $0.24 earnings per share. The company’s revenue was up 15.3% compared to the same quarter last year. On average, analysts predict that Sucampo Pharmaceuticals, Inc. will post $1.01 earnings per share for the current fiscal year.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply